chang tp
number share mn
price month
challeng highlight result
obstacl overcom expect progress
event takeda releas result juli plan
minut confer call day guidanc releas
may result attract neg respons lead slump
takeda share-pric expect result provid takeda
first opportun dispel uncertainti lack clariti around
limit inform comment full-year outlook first-
quarter result first quarterli result sinc shire
merger lack clariti data takeda use prior-year
comparison left market uncertain think market may focu
current statu outlook blood product busi
hemophilia drug perform velcad result compani
outlook gener launch spend versu cost budget
achiev cost synergi transfer dry-ey drug xiidra
novarti progress negoti sale non-cor
asset disclosur balanc sheet cash flow statement
progress versu full-fi outlook likelihood make guidanc
believ takeda would releas inform point
normal circumst investor view compani
oper state evolut gener version velcad
launch alon allow takeda make
substanti progress versu guidanc think compani unlik
revis guidanc market could question disclosur
signific differ result full-year guidanc core
earn figur seen disappoint
share price like bottom takeda share fell
compani releas result earn guidanc may think
phase investor sell close posit takeda may
end think japanes investor still wait-and-se
approach mostli take long-onli posit although
investor may sens risk own takeda low
share price oversea investor us asia seem look
someth trigger rebound investor europ
monitor situat also impress european
investor sharehold shire sold takeda stake
withdrawn think us investor may lose interest takeda
acquisit shire number major corpor acquisit
home territori go bristol-my squibb celgen
allergan time money situat
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
profit tax
issuanc retir stock
net chang cash
number share mn
compani mention price
